Open AccessDetection of SARS-CoV-2 at the point of care
Author(s) -
Michael J. Loeffelholz,
YiWei Tang
Publication year - 2021
Publication title -
bioanalysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.566
H-Index - 58
eISSN - 1757-6199
pISSN - 1757-6180
DOI - 10.4155/bio-2021-0078
Subject(s) - covid-19 , point of care testing , medicine , point of care , coronavirus , virology , severe acute respiratory syndrome , intensive care medicine , severe acute respiratory syndrome coronavirus , public health , epidemiology , immunology , infectious disease (medical specialty) , pathology , outbreak , disease
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiologic agent of COVID-19. Testing for SARS-CoV-2 infection is a critical element of the public health response to COVID-19. Point-of-care (POC) tests can drive patient management decisions for infectious diseases, including COVID-19. POC tests are available for the diagnosis of SARS-CoV-2 infections and include those that detect SARS-CoV-2 antigens as well as amplified RNA sequences. We provide a review of SARS-CoV-2 POC tests including their performance, settings for which they might be used, their impact and future directions. Further optimization and validation, new technologies as well as studies to determine clinical and epidemiological impact of SARS-CoV-2 POC tests are needed.